Verified all three cited sources by WebFetch. (1) The Hassan Senate press release (PRIMARY) is reachable and the cited quote appears VERBATIM: "The Medication Affordability and Patent Integrity Act would require manufacturers to certify that they have not made inconsistent statements to the two agencies, helping stop abuses of the patent system." It documents Hassan co-introducing/authoring bipartisan legislation to crack down on drug-manufacturer patent abuses that delay generics — leadership, not a mere vote. (2) The CSRxP source (REPUTABLE_SECONDARY) is reachable and confirms the Senate HELP Committee advanced the Medication Affordability and Patent Integrity Act (S. 2658) alongside the Biosimilar Red Tape Elimination Act (S. 1954). (3) Quiver Quantitative (REPUTABLE_SECONDARY) is reachable and confirms "Margaret Wood Hassan is the main sponsor" of S. 2658 and the June 17, 2026 committee action, "Ordered to be reported with an amendment in the nature of a substitute favorably." The CHAMPIONED bar for genuine LEADERSHIP is met: Hassan is the primary sponsor/author who drove the bill through committee, matching the promise to keep working to lower drug costs by cracking down on patent abuses that delay generics. It falls short of FULL only because the bill has advanced through committee but is not yet enacted; the promise was to "continue working," and the leadership evidence is strong. CHAMPIONED is the correct rating.